EyePoint Pharmaceuticals (STU:PV3B) Additional Paid-In Capital : €923.93 Mil(As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is EyePoint Pharmaceuticals Additional Paid-In Capital?

EyePoint Pharmaceuticals's quarterly additional paid-in capital increased from Jun. 2023 (€712.39 Mil) to Sep. 2023 (€736.29 Mil) and increased from Sep. 2023 (€736.29 Mil) to Dec. 2023 (€923.93 Mil).

EyePoint Pharmaceuticals's annual additional paid-in capital increased from Dec. 2021 (€666.05 Mil) to Dec. 2022 (€723.95 Mil) and increased from Dec. 2022 (€723.95 Mil) to Dec. 2023 (€923.93 Mil).

EyePoint Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for EyePoint Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Additional Paid-In Capital Chart

EyePoint Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

425.49

434.31

666.05

723.95

923.93

EyePoint Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															723.95	719.21	712.39	736.29	923.93

EyePoint Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

EyePoint Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

EyePoint Pharmaceuticals (STU:PV3B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (STU:PV3B) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

EYPT:USA

Address

480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472

Website

https://www.eyepointpharma.com

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals (STU:PV3B) Headlines

No Headlines